|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5527527A
(en)
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5260210A
(en)
|
1989-09-27 |
1993-11-09 |
Rubin Lee L |
Blood-brain barrier model
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
FR2705194A1
(fr)
|
1993-05-21 |
1994-11-25 |
Transgene Sa |
Animal transgénique exprimant une transferrine d'origine humaine.
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
WO1999000150A2
(en)
|
1997-06-27 |
1999-01-07 |
Regents Of The University Of California |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US7241449B1
(en)
|
1999-04-12 |
2007-07-10 |
Aventis Pasteur Limited |
Transferrin receptor genes of moraxella
|
|
JP2003513016A
(ja)
|
1999-08-30 |
2003-04-08 |
ニューヨーク・ユニバーシティ |
レセプタータンパク質チロシンキナーゼのドメイン、およびそのリガンドの結晶構造
|
|
JP2003525038A
(ja)
|
2000-02-08 |
2003-08-26 |
ユニバーシティー オブ ブリティッシュ コロンビア |
治療薬をスクリーニングするための組成物および方法
|
|
JP2001238681A
(ja)
|
2000-03-03 |
2001-09-04 |
Japan Science & Technology Corp |
共培養による血液脳関門再構築モデル
|
|
US6743893B2
(en)
|
2000-11-30 |
2004-06-01 |
The Uab Research Foundation |
Receptor-mediated uptake of peptides that bind the human transferrin receptor
|
|
DK1355919T3
(da)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
|
|
JP2005501230A
(ja)
|
2001-06-29 |
2005-01-13 |
ワイス |
血液−脳関門透過の予測に有用な方法および組成物
|
|
US20030226155A1
(en)
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
|
ES2411007T3
(es)
|
2001-10-10 |
2013-07-04 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
|
US20030074141A1
(en)
|
2001-10-15 |
2003-04-17 |
Camitro Corporation |
Meta-models for predicting blood brain barrier penetration based on simple physicochemical descriptors
|
|
US20060130158A1
(en)
*
|
2002-08-30 |
2006-06-15 |
Turner Andrew J |
Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
CA2522700A1
(en)
|
2003-04-18 |
2004-11-04 |
Cytovia, Inc. |
Methods of treating diseases responsive to induction of apoptosis and screening assays
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
US20050170394A1
(en)
|
2004-01-30 |
2005-08-04 |
Xenoport, Inc. |
GLUT1 transporters expressed in blood brain barrier cells
|
|
GB0403490D0
(en)
|
2004-02-17 |
2004-03-24 |
Daniolabs Ltd |
Screening methods
|
|
FR2871162B1
(fr)
|
2004-06-02 |
2007-06-29 |
Univ Paris 7 Denis Diderot |
Materiau de surface modifiee, son procede de preparation et ses utilisations
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EP2325206B1
(en)
|
2004-11-12 |
2014-03-19 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
US8084254B2
(en)
|
2004-11-29 |
2011-12-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Human blood brain barrier model
|
|
PL1699826T3
(pl)
*
|
2005-01-05 |
2009-08-31 |
F Star Biotechnologische Forschungs Und Entw M B H |
Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność
|
|
US8900865B2
(en)
|
2005-12-14 |
2014-12-02 |
The Invention Science Fund I, Llc |
Blood brain barrier device
|
|
JP5113332B2
(ja)
|
2005-12-19 |
2013-01-09 |
正美 丹羽 |
血液脳関門インヴィトロ・モデル、病態血液脳関門インヴィトロ・モデル、及びこれを用いた薬物スクリーニング方法、病態血液脳関門機能解析方法、病因解析方法
|
|
US7744879B2
(en)
|
2006-06-07 |
2010-06-29 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
US20080044847A1
(en)
|
2006-06-23 |
2008-02-21 |
Shusta Eric V |
Blood-Brain Barrier Model
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
SG173332A1
(en)
|
2006-08-01 |
2011-08-29 |
Pieris Ag |
Muteins of tear lipocalin and methods for obtaining the same
|
|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
ES2975748T3
(es)
|
2007-06-26 |
2024-07-12 |
F Star Therapeutics Ltd |
Presentación de agentes de unión
|
|
AU2008273094B2
(en)
|
2007-07-12 |
2013-05-09 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
|
CA3052615A1
(en)
|
2008-01-31 |
2009-08-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
JP5723769B2
(ja)
|
2008-06-03 |
2015-05-27 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
WO2010014622A2
(en)
|
2008-07-28 |
2010-02-04 |
Fondazione Istituto Firc Di Oncologica Molecolare (Ifom) |
In vitro model for modulating the blood brain barrier and methods of screening
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
SG175233A1
(en)
|
2009-04-22 |
2011-11-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
|
ES2948572T3
(es)
|
2009-07-08 |
2023-09-14 |
Kymab Ltd |
Modelos de roedores y moléculas terapéuticas
|
|
US8417465B2
(en)
|
2009-11-04 |
2013-04-09 |
Cfd Research Corporation |
Synthetic microfluidic blood-brain barrier
|
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
|
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
|
KR101755965B1
(ko)
|
2010-10-29 |
2017-07-07 |
에프. 호프만-라 로슈 아게 |
Ｉｌ３３ ｎ―말단 도메인 결실을 갖는 염증의 쥣과 모델
|
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
|
KR102188544B1
(ko)
|
2010-11-30 |
2020-12-08 |
제넨테크, 인크. |
저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
|
|
KR20140026372A
(ko)
|
2011-02-02 |
2014-03-05 |
이무노퓨처 아이앤씨. |
혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
|
|
JP5972915B2
(ja)
|
2011-03-16 |
2016-08-17 |
アムジエン・インコーポレーテツド |
Ｆｃ変異体
|
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
AU2012244816B2
(en)
|
2011-04-20 |
2015-12-10 |
Roche Glycart Ag |
Method and constructs for the pH dependent passage of the blood-brain-barrier
|
|
EA201892619A1
(ru)
*
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP4011913A1
(en)
|
2011-06-30 |
2022-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
EP2546268A1
(en)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalising immunoglobulin
|
|
EP2568051A1
(en)
|
2011-09-07 |
2013-03-13 |
Stallergenes S.A. |
Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
|
|
DK177327B1
(en)
|
2011-12-23 |
2013-01-14 |
Entomopharm Aps |
OPTIMIZED INSECT BASED EX VIVO MODEL FOR EXAMINATION OF BLOOD BRAIN BARRIER penetration and method of exposing the insect brain to chemical compounds
|
|
CN113527469A
(zh)
|
2012-02-09 |
2021-10-22 |
中外制药株式会社 |
抗体的Fc区变异体
|
|
US9475840B2
(en)
|
2012-02-27 |
2016-10-25 |
Universitat De Barcelona |
Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
|
|
PL2825553T3
(pl)
|
2012-03-14 |
2018-12-31 |
Regeneron Pharmaceuticals, Inc. |
Wieloswoiste cząsteczki wiążące antygen i ich zastosowanie
|
|
EP2825557B1
(en)
|
2012-03-16 |
2017-06-28 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Soluble engineered monomeric fc
|
|
CA2871468C
(en)
|
2012-04-23 |
2021-09-21 |
Nrl Pharma, Inc. |
Lactoferrin fusion protein and method for preparation thereof
|
|
US20150353639A1
(en)
|
2012-05-21 |
2015-12-10 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
WO2013184514A1
(en)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
EP2862875B1
(en)
|
2012-06-14 |
2023-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
|
US9513280B2
(en)
|
2012-08-28 |
2016-12-06 |
University Of Utah Research Foundation |
Microfluidic biological barrier model and associated method
|
|
HUE045144T2
(hu)
|
2012-08-29 |
2019-12-30 |
Hoffmann La Roche |
Véragygát-shuttle
|
|
US10590393B2
(en)
|
2012-11-08 |
2020-03-17 |
Wisconsin Alumni Research Foundation |
Retinoic acid enhanced human stem cell derived blood brain barrier model
|
|
US9932559B2
(en)
|
2012-11-16 |
2018-04-03 |
The Johns Hopkins University |
Platform for creating an artificial blood brain barrier
|
|
AU2013355324A1
(en)
|
2012-12-04 |
2015-05-21 |
Abbvie Inc. |
Blood-brain barrier (BBB) penetrating dual specific binding proteins
|
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014144060A1
(en)
|
2013-03-15 |
2014-09-18 |
Alper Biotech, Llc |
Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
|
|
WO2014203087A1
(en)
|
2013-03-26 |
2014-12-24 |
Biocant - Centro De Inovação Em Biotecnologia |
A human blood-brain barrier model derived from stem cells
|
|
TWI523945B
(zh)
|
2013-03-29 |
2016-03-01 |
Nat Univ Chung Cheng |
Establishment of blood - brain barrier model in
|
|
US20160068613A1
(en)
|
2013-04-29 |
2016-03-10 |
Hoffmann-La Roche Inc. |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
CA3166758A1
(en)
|
2013-05-14 |
2014-11-20 |
California Institute Of Technology |
Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
|
|
PH12021550015A1
(en)
|
2013-05-20 |
2022-05-11 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
RU2655439C2
(ru)
|
2013-05-31 |
2018-05-28 |
Займворкс Инк. |
Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
|
|
MA38797A1
(fr)
|
2013-08-02 |
2018-06-29 |
Hoffmann La Roche |
Protéine de fusion thérapeutique
|
|
EP3035969B1
(en)
|
2013-08-19 |
2022-08-03 |
S.M. Discovery Holdings Inc. |
Peptidic nanodelivery composition targeting two receptors
|
|
US11261262B2
(en)
|
2013-09-03 |
2022-03-01 |
Novimmune Sa |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
|
PT3071597T
(pt)
|
2013-11-21 |
2020-10-08 |
Hoffmann La Roche |
Anticorpos anti-alfa-sinucleína e métodos de utilização
|
|
WO2015098989A1
(ja)
|
2013-12-25 |
2015-07-02 |
Ｊｃｒファーマ株式会社 |
血液脳関門を通過する新規抗トランスフェリン受容体抗体
|
|
ES2895752T3
(es)
|
2014-01-03 |
2022-02-22 |
Hoffmann La Roche |
Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
|
|
ES2864160T3
(es)
|
2014-01-06 |
2021-10-13 |
Hoffmann La Roche |
Módulos lanzadera de la barrera hematoencefálica monovalentes
|
|
US9629801B2
(en)
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
RU2016136989A
(ru)
|
2014-02-19 |
2018-03-22 |
Ф.Хоффманн-Ля Рош Аг |
Шаттл для гематоэнцефалического барьера
|
|
US10774119B2
(en)
|
2014-05-22 |
2020-09-15 |
Pieris Pharmaceuticals Gmbh |
Specific-binding polypeptides and uses thereof
|
|
US20160002343A1
(en)
|
2014-06-11 |
2016-01-07 |
Abbvie Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
EP2995949A1
(en)
|
2014-09-09 |
2016-03-16 |
Institut Pasteur |
New in vitro blood brain barrier model
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
CN107001473B
(zh)
|
2014-11-19 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
抗-运铁蛋白受体抗体及使用方法
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
EP3230439B1
(en)
|
2014-12-09 |
2023-08-09 |
National Research Council Of Canada |
Human blood brain barrier model
|
|
WO2016202343A1
(en)
|
2015-06-19 |
2016-12-22 |
Aalborg Universitet |
A triple co-culture model of the blood-brain barrier using primary porcine brain endothelial cells, porcine pericytes and porcine astrocytes
|
|
IL302486A
(en)
*
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
CN107531788B
(zh)
|
2015-06-24 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对her2和血脑屏障受体特异性的三特异性抗体及使用方法
|
|
TWI769982B
(zh)
*
|
2015-06-24 |
2022-07-11 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之抗人類運鐵蛋白受體抗體
|
|
JP6914193B2
(ja)
|
2015-06-24 |
2021-08-04 |
Ｊｃｒファーマ株式会社 |
Ｂｄｎｆを含む融合蛋白質
|
|
CA2987641A1
(en)
|
2015-07-06 |
2017-01-12 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
|
WO2017035119A1
(en)
|
2015-08-24 |
2017-03-02 |
National University Of Singapore |
Blood brain barrier model in a 3d co-culture microfluidic system
|
|
CN114057885A
(zh)
|
2015-10-02 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
|
EP3411406B1
(en)
|
2016-02-05 |
2025-04-09 |
Genmab A/S |
Multispecific antigen-binding molecule with improved internalization characteristics
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
US20200317749A1
(en)
|
2016-07-01 |
2020-10-08 |
Denali Therapeutics Inc. |
Albumin variants for enhanced serum half-life
|
|
CN109476728A
(zh)
|
2016-07-14 |
2019-03-15 |
生命北极公司 |
脑部递送蛋白
|
|
EP3494216B1
(en)
|
2016-08-06 |
2025-10-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
EP3556399A1
(en)
|
2016-12-19 |
2019-10-23 |
Hanmi Pharm. Co., Ltd. |
Brain targeting long-acting protein conjugate
|
|
EP3561058B1
(en)
|
2016-12-26 |
2025-07-23 |
JCR Pharmaceuticals Co., Ltd. |
Fusion protein including bdnf
|
|
NZ752703A
(en)
|
2016-12-26 |
2022-09-30 |
Japan Chem Res |
Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
|
|
US10457717B2
(en)
|
2017-02-17 |
2019-10-29 |
Denali Therapeutics Inc. |
Engineered polypeptides
|
|
WO2018152359A1
(en)
|
2017-02-17 |
2018-08-23 |
Denali Therapeutics Inc. |
Anti-tau antibodies and methods of use thereof
|
|
FI3583120T3
(fi)
|
2017-02-17 |
2023-01-13 |
|
Muunneltuja transferriinireseptoria sitovia polypeptidejä
|
|
US10143187B2
(en)
|
2017-02-17 |
2018-12-04 |
Denali Therapeutics Inc. |
Transferrin receptor transgenic models
|
|
EP3600394A4
(en)
|
2017-03-22 |
2021-04-14 |
Research Corporation Technologies, Inc. |
MANIPULATED STABLE CH2-POLYPEPTIDES
|
|
MX2019012381A
(es)
|
2017-05-18 |
2020-01-23 |
Hoffmann La Roche |
Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.
|
|
WO2019032955A1
(en)
|
2017-08-10 |
2019-02-14 |
Denali Therapeutics Inc. |
MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
|
|
WO2019055841A1
(en)
|
2017-09-14 |
2019-03-21 |
Denali Therapeutics Inc. |
ANTI-TREM2 ANTIBODIES AND METHODS OF USE
|
|
CA3076369A1
(en)
|
2017-10-02 |
2019-04-11 |
Denali Therapeutics Inc. |
Fusion proteins comprising enzyme replacement therapy enzymes
|
|
CA3080351A1
(en)
|
2017-11-02 |
2019-05-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
|
WO2019094608A1
(en)
|
2017-11-08 |
2019-05-16 |
Denali Therapeutics Inc. |
Anti-bace1 antibodies and methods of use thereof
|
|
WO2019140050A1
(en)
|
2018-01-10 |
2019-07-18 |
Denali Therapeutics Inc. |
Transferrin receptor-binding polypeptides and uses thereof
|
|
US20210046189A1
(en)
|
2018-03-30 |
2021-02-18 |
HANMl PHARM. CO., LTD. |
Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
|
|
JP7517997B2
(ja)
|
2018-06-18 |
2024-07-17 |
デナリ セラピューティクス インコーポレイテッド |
プログラニュリンを含む融合タンパク質
|
|
SG11202101273VA
(en)
|
2018-08-16 |
2021-03-30 |
Denali Therapeutics Inc |
Engineered bispecific proteins
|
|
KR20210074279A
(ko)
|
2018-08-22 |
2021-06-21 |
데날리 테라퓨틱스 인크. |
항-her2 폴리펩타이드 및 이의 사용방법
|
|
US12351642B2
(en)
|
2018-09-14 |
2025-07-08 |
Ossianix, Inc. |
TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
|
|
EP3866861A4
(en)
|
2018-10-16 |
2022-09-07 |
Denali Therapeutics Inc. |
METHODS OF TREATMENT AND MONITORING OF PROGRANULIN-ASSOCIATED DISEASES
|
|
WO2020112889A2
(en)
|
2018-11-26 |
2020-06-04 |
Denali Therapeutics Inc. |
Methods for treating dysregulated lipid metabolism
|
|
MA54450A
(fr)
|
2018-12-10 |
2021-10-20 |
Denali Therapeutics Inc |
Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation
|
|
MX2021011612A
(es)
|
2019-04-03 |
2021-12-10 |
Denali Therapeutics Inc |
Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa.
|
|
AU2020411480B2
(en)
|
2019-12-23 |
2023-12-21 |
Denali Therapeutics Inc. |
Progranulin variants
|
|
KR20220131246A
(ko)
|
2020-01-13 |
2022-09-27 |
데날리 테라퓨틱스 인크. |
항-trem2 항체 및 이의 사용 방법
|
|
EP4100419A4
(en)
|
2020-02-07 |
2024-05-29 |
Denali Therapeutics Inc. |
METHODS OF TREATING HUNTER SYNDROME
|
|
CA3170338A1
(en)
|
2020-02-19 |
2021-08-26 |
Denali Therapeutics Inc. |
Engineered anti-her2 bispecific proteins
|
|
MA71661A
(fr)
|
2020-10-14 |
2025-05-30 |
Denali Therapeutics Inc. |
Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
|